Treatment of al amyloidosis with melphalan, prednisone, and colchicine

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17-60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.

Original languageEnglish (US)
Pages (from-to)683-687
Number of pages5
JournalArthritis & Rheumatism
Volume29
Issue number5
DOIs
StatePublished - May 1986

Fingerprint

Melphalan
Colchicine
Amyloidosis
Prednisone
Combination Drug Therapy
Therapeutics
Indocyanine Green
Nephrotic Syndrome
Cardiomyopathies
Amyloid
Disease Progression
Immunoglobulins
Liver

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Treatment of al amyloidosis with melphalan, prednisone, and colchicine. / Benson, Merrill D.

In: Arthritis & Rheumatism, Vol. 29, No. 5, 05.1986, p. 683-687.

Research output: Contribution to journalArticle

@article{c5dfb6defbcf4b2284f59695782602ee,
title = "Treatment of al amyloidosis with melphalan, prednisone, and colchicine",
abstract = "Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17-60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.",
author = "Benson, {Merrill D.}",
year = "1986",
month = "5",
doi = "10.1002/art.1780290515",
language = "English (US)",
volume = "29",
pages = "683--687",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of al amyloidosis with melphalan, prednisone, and colchicine

AU - Benson, Merrill D.

PY - 1986/5

Y1 - 1986/5

N2 - Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17-60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.

AB - Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17-60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=0022510530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022510530&partnerID=8YFLogxK

U2 - 10.1002/art.1780290515

DO - 10.1002/art.1780290515

M3 - Article

C2 - 3718560

AN - SCOPUS:0022510530

VL - 29

SP - 683

EP - 687

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -